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This collection of summaries on endoscopic diagnosis of Barrett’s esophagus (BE) includes the best endoscopic
markers of the extent of BE; the interpretation of the diagnosis of ultra-short BE; the criteria for endoscopic
grading; the sensitivity and specificity of endoscopic diagnosis; capsule and magnifying endoscopy; narrow band
imaging; balloon cytology; the distinction between focal and diffuse dysplasia; the techniques for endoscopic de-
tection of dysplasia and the grading systems; and the difficulty of interpretation of inflammatory or regenerative
changes.
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Concise summaries
• A new modification may be necessary for the
Prague C&M criteria, taking into account the
technical difficulty for the definition of gas-
troesophageal junction (GEJ) by endoscopic
landmarks. However, the reliability of the
Prague criteria, evaluated by a measure of in-
terobserver agreement for recognizing differ-
ent lengths of Barrett’s esophagus (BE) and
the position of the GEJ indicated by the prox-
imal margin of the gastric folds was very
satisfactory.
• Ultra-short segment Barrett’s mucosa
(USSBE) or intestinal metaplasia (IM) at
the junction is common. To put it under
surveillance comes with excessive demands,
and it should be ignored.
• Contrast endoscopy appears to be the most
practical way to detect islands of IM after
doi: 10.1111/j.1749-6632.2011.06045.x
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ablation. Endomicroscopy has potential but
is less practical for this goal. Acetic acid
chromoendoscopy has good potential but is
not widely used. Utilizing the ACG guidelines,
the positive predictive value (PPV) of endo-
scopically identifying BE would vary consid-
erably depending on the number of biopsies
obtained and the length of the Barrett’s epithe-
lium. Further advances in video capsule en-
doscopy technology, allowing for even better
visualization of the Z-line and possible tissue
acquisition, could render the performance pa-
rameters of this technique favorable compared
to standard upper endoscopy.
• String capsule endoscopy (SCE), allowing con-
trolledmovementwithin the esophagus, seems
to have better accuracy in the diagnosis of BE.
Narrow band imaging (NBI) has changed the
approach to Barrett’s in specialized centers in
that it allows a more detailed view and map-
ping of the affected segment. It is used as an
adjunct to conventional white-light endoscopy
for targeted investigation of suspicious areas.
• However, trimodal imaging is still unable to be
considered superior to random four-quadrant
biopsies (4QB) takenwith standard endoscopy
with regard to detection of lesions.
• Current evidence shows that autofluorescence-
based strategies are still expensive, not widely
available, nonstandardized, and even in ex-
pert hands suffer from an unacceptably high
false positive rate to make it viable at this time.
Balloon cytology has low sensitivity but high
specificity to detect low-grade dysplasia in BE.
Anew typeofmechanical balloonandancillary
molecular studymay improve the sensitivity of
this technique.
• DNA ploidy determination appears to be a
powerful method for determination of can-
cer risk and progression in BE-related disease
and can be carried out by improved image cy-
tometry that is easier to use and more reliable
than flow cytometry (FC). With histology as
the gold standard, balloon cytology has been
found to have low sensitivity, but reasonable
to high specificity. There is a need to minimize
the discrepancies in interpretation ofmorpho-
logic dysplasia between Western and Japanese
pathologists and to reach a uniform consensus
on the nomenclature of neoplastic precursor
lesions.
• Endoscopic FED gives a comparable result
to that obtained with four quadrants biop-
sies taken every 1 cm. High-resolution (HR)
endoscopy has likely become the default
standard imaging technique for best selec-
tion of biopsies and endoscopic diagnosis of
dysplasia.
1. What is the most consistent landmark
for the endoscopic diagnosis of BE? What
are the best markers of the distal extent of
endoscopic BE by use of standard
equipment?
Norihisa Ishimura and Yuji Amano
amano@med.shimane-u.ac.jp
A reliable diagnosis of BE depends on the accurate
endoscopic recognition of the anatomic landmarks
at the GEJ and squamocolumnar junction (SCJ). To
standardize the objective diagnosis of endoscopic
BE, the PragueC&Mcriteria was proposed by a sub-
group of the International Working Group for the
Classification of Oesophagitis (IWGCO).1 In this
system, the landmark for the GEJ is the proximal
end of the gastric folds, not the distal end of palisade
vessels, which are used to endoscopically identify the
GEJ in Japan. Although the Prague C&Mcriteria are
clinically relevant, an important shortcoming of this
system may be failure to identify short segment BE
(SSBE),2 a lesion that is found frequently in most
Asian countries, including Japan.
Our aim was to compare the diagnostic yield for
BE when using the gastric folds versus palisade ves-
sels as a landmark for the GEJ, and we evaluated
interobserver diagnostic concordance.3
Eighty-four endoscopists classified 30 patients
with BE by viewing projected endoscopic pho-
tographs. The endoscopists were asked to identify
the GEJ, first by using palisade vessels as a landmark
and then by using the gastric folds. Endoscopists
were divided into groups according to years in prac-
tice as an endoscopist, presence, or absence of board
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certification from the JapanGastroenterological En-
doscopy Society, and whether they had taken any
special endoscopic training courses on GERD. The
 coefficient of reliability was calculated for each
group.
Results
Of the 30 cases, 17 had clearly visible palisade ves-
sels, whereas the vessels could not be found in 13
cases. In 17 cases with clearly visible palisade vessels,
the  value was 0.16, an unacceptably low value of
concordance over chance agreement. The value of
trained endoscopists was significantly higher than
that of nontrained endoscopists. In 13 cases where
gastric folds were used as a landmark of GEJ, the
 values were lower than those in palisade vessels
criteria. Trained endoscopists also showed a higher
 value than nontrained endoscopists. To assess the
effectiveness of the systematic education and train-
ing about the PragueC&Mcriteria, the same trained
endoscopists were thoroughly explained this crite-
ria, and the same test was repeated twomonths later.
As a result, the diagnostic concordance significantly
increased from 0.17 to 0.35 after the education and
training about the criteria and the use of the proxi-
mal end of gastric folds as a landmark. In the evalu-
ation by the still photographs, gastric folds showed
a higher  value than palisade vessels as a landmark
of the GEJ.
The most important weakness of proximal ends
of gastric folds is that the diagnostic concordance
is low in SSBE, which is difficult to identify the
proximal endof gastric folds.Moreover, the position
of the proximal margin of the gastric fold can easily
change by altering the degree of air deflation with
endoscopy (Table 1).
Palisade vessels can be found easily when the
lower esophagus is adequately distended. However,
the visual identification of palisade vessels may be
disturbed by several factors including mucosal in-
flammation, dysplastic changes, and the presence
of a thick double muscularis mucosa. Insufficient
extension and inadequate stretch of the esopha-
gus under conscious sedation may also disturb the
identification of palisade vessels. Thus, neither of
the landmarks of GEJ—gastric folds and palisade
vessels—are the ideal, for different reasons, and are
difficult to identify accurately and consistently in all
patients with BE.4
Table 1. Technical difficulty for definition of GEJ by en-
doscopic landmarks
Endoscopic landmark Technical
of GEJ difficulty
Proximal ends of gastric
folds (C&M criteria)
The position can easily
change by air deflation
Unable to recognize the
fold in cases with severe
atrophic gastritis
Distal ends of palisade
vessels (Japanese
criteria)
Difficult to identify when
inflammation and
dysplastic change are
present
Insufficient distention of
the lower esophagus
under conscious
sedation may disturb
the identification of the
vessels
Conclusion
A new modification may be necessary for the C&M
criteria, as more accurate and suitable criteria for
both patients with long segment BE (LSBE) and
SSBE. Also, systematic education and training are
important to improve the diagnostic consistency in
patients with SSBE, especially for less experienced
endoscopists.
2. Is the diagnosis of USSBE beneficial for
patient care?
Henry D. Appelman
appelman@umich.edu
To answer this question, we need to know the defi-
nition of USSBE. This seems to be the same as IM,
identified by the presence of goblet cells, at the GEJ,
on the columnar side of the SCJ.5 To satisfy this def-
inition, does the SCJ have to be normal or can it be
exaggerated? This is not clear. Because this junction
region is so small, a tiny patch of IM in a biopsy
from the junction may be either on the esophageal
or on the gastric cardiac side, and there is no way to
tell from the microscopic exam.
According to the 2008 American College of Gas-
troenterology (ACG) Practice Parameters Com-
mittee definition, BE is “a change in the distal
esophageal epithelium of any length that can be
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recognized as columnar type mucosa at endoscopy
and is confirmed to have IM by biopsy of the
tubular esophagus.”6 This is somewhat different
from the 2006 definition from the British Society
of Gastroenterology in which BE is defined as “an
endoscopically apparent area above the esopha-
gogastric junction that is suggestive of Barrett’s,
which is supported by the finding of columnar-
lined esophagus on histology.”7 In this definition,
the presence of goblet cells are not a requirement
for diagnosis, presumably because limited sampling
may miss them. However, USSBE does not satisfy
either the American or British endoscopic require-
ments for the diagnosis of Barrett’s mucosa, so it
does not deserve to be given the Barrett name.
How common is USSBE? About 15% of peo-
ple with normal-appearing SCJs have IM, so this
clearly is not seen endoscopically.8 About a third or
more of people with jagged, irregular, or especially
prominent SCJs have IM. This irregularity or es-
pecial prominence can be seen endoscopically, so,
perhaps, this may be considered to be a modifica-
tion of the endoscopic requirements for Barrett’s
mucosa. However, if these data are correct, then it is
likely that millions of people have USSBE.
Barrett’s mucosa is only important because it has
a cancer risk, so does USSBE have a cancer risk com-
parable to that of typical Barrett’s mucosa? Some
studies suggest that the length of columnar-lined
esophagus of Barrett’s mucosa is a significant risk
factor in the development of dysplasia and carci-
noma. One study indicates that the risk for ade-
nocarcinoma in patients with short segment Bar-
rett’s is not substantially lower than that in long
segment disease, although the results of that study
did suggest a small increase in risk for neoplastic
progression with increasing segment length. In this
study, seven patients had IM at the junction—that
is, USSBE—without endoscopic Barrett’s mucosa,
and no cancers were detected during over 23 person
years of follow-up.9 Therefore, there seems to be no
data proving that IMGEJ has a cancer risk compara-
ble to long segment Barrett’s mucosa or even short
segment Barrett’s mucosa. In fact, there is no data
proving that USSBE has any increased cancer risk.
What is the downside for labeling a patient as
having Barrett’s mucosa based simply on IM at the
junction? First, there is the patient’s anxiety because
of perceived cancer risk, which then leads to the
need for repeat surveillance endoscopy and biopsy.
Insurability problems are superimposed, and, in ad-
dition, it is commonly difficult to find that IM at
subsequent endoscopy and biopsy.
In summary, USSBE or IM at the junction is com-
mon. To put it under surveillance comes with exces-
sive demands on our medical resources including
endoscopists, biopsies, and pathologists to interpret
the biopsies. It does not satisfy any of the definitions
of Barrett’s mucosa because it does not have the en-
doscopic findings. It does not have an established
cancer risk, and it is difficult to find at subsequent
endoscopies. These facts lead to this obvious conclu-
sion: USSBE, also known as IM at the GEJ, should
be ignored.
3. What is the value of the Prague C&M
criteria for standardization of the
endoscopic grading of BE and its
progression over time?
Roberto Penagini and Andrea Tenca
roberto.penagini@unimi.it
Validated endoscopic descriptions of BE are lacking.
The International Working Group for the Classifi-
cation of Oesophagitis (IWGCO) has recently vali-
dated criteria for the endoscopic description of BE.2
These criteria are called the Prague C&M because
they were developed during the United European
Gastroenterology Week in Prague and are based on
measurement of both circumferential (C) andmaxi-
mal (M) extent ofmetaplasia (Fig. 1). In the original
paper, criteria were externally validated by 29 expert
endoscopists. The reliability coefficient (RC), amea-
sure of interobserver agreement, for recognizing dif-
ferent lengths of BE (C&M values), and the position
of the GEJ indicated by the proximal margin of the
Figure 1. ThePragueC&Mcriteria by the InternationalWork-
ing Group for the Classification of Oesophagitis (IWGCO).2
With permission from Elsevier.
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gastric folds were very good, ranging from 0.88 to
0.94. Recognition of≤1 cmof BEwas, however, only
slightly reliable (RC of 0.21). Recently, criteria have
also been validated by 16 gastroenterology trainees
and RCs were similarly high, ranging from 0.93 to
0.97.10 These data show that the Prague C&M crite-
ria can reliably be used in clinical practice both by
experts and trainees after adequate teaching. A re-
cent study in Japan has highlighted the importance
of training on Prague criteria and has shown that
the RC of 25 experienced endoscopists for identifi-
cation of the GEJ was poor when assessed without
training and it improved markedly after training.3
Considering that validation of the Prague criteria
has been done using video clips or still photographs,
another study from Japan involving experienced en-
doscopists has suggested that RC for recognizing the
position of the GEJ is less during live endoscopy
than with still photographs.4 A study by Kinjo
et al. has questioned the use of the proximal mar-
gin of gastric fold for identification of the GEJ in
the Japanese population where gastric folds are less
visible because of a high prevalence of atrophic gas-
tritis.11 In this population, the lower limit of the
palisade vessels (using HR endoscopy [HRE]) has
been suggested to be a more reliable indicator. Fi-
nally, ongoing studies will assess whether the Prague
C&M criteria have an impact on overall patients’
outcome.
4. What are the means of detecting focal
islands of SIM not visible at conventional
endoscopy?
Gary W. Falk
gary.falk@uphs.upenn.edu
There are two scenarios where one is trying to ad-
dress focal islands of IM. The first is an attempt to
detect IM within the mosaic of columnar epithe-
lium that is characteristic of a typical BE segment.
The second is to detect islands of IM after endo-
scopic ablation by any of a variety of differentmeth-
ods. The current tools available to accomplish this
task are chromoendoscopy, contrast endoscopy, and
confocal endomicroscopy.
Methylene blue12 is a vital stain that selectively
diffuses into the cytoplasm of absorptive epithe-
lium of the small intestine and colon. The presence
of staining in the esophagus indicates the presence of
IM. However, there is no agreement on application
technique in terms of the concentration, volume,
and “dwell time” for methylene blue chromoen-
doscopy and interpretation of staining is subjective.
Methylene blue chromoendoscopy12 also adds addi-
tional procedure time. A recentmeta-analysis found
that methylene blue chromoendoscopy resulted in
no incremental yield when compared to random
biopsies for the detection of IM, high-grade dyspla-
sia, or early cancer.
On the other hand, application of acetic acid13
in conjunction with magnification endoscopy14 can
enhance the detection of IM both before and after
ablation therapy. However, this requires pit pattern
interpretation and magnification endoscopic tech-
niques, thereby making this method of uncertain
clinical utility.
A variety of optical imaging enhancements have
been developed to allow for detailed inspection of
the mucosal and vascular surface patterns. NBI15
involves the placement of optical filters that narrow
the band width of white light to blue light. This
allows for detailed imaging of the mucosal and vas-
cular surface patterns in BE without the need for
chromoendoscopy. There are also two postprocess-
ing software-driven systems to accomplish similar
visualization (I-scan and FICE). A recent systematic
review found that NBI has a sensitivity of 77–100%
and a specificity of 79–94% for the detection of
IM. The overall accuracy is estimated to be approx-
imately 88–96%. There are a number of unresolved
issues regarding NBI, including the use of multi-
ple classification schemes for mucosal and vascular
patterns, image interpretation based on still images
instead of real time endoscopy, the use of optical
versus electronic zoom, and the use of study popu-
lations enriched with early neoplasia in tertiary care
centers.
Confocal laser endomicroscopy (CLE)16 is a new
endoscopic imaging technique that allows for sub-
surface imaging and in vivo histologic assessment of
the mucosal layer during standard white light en-
doscopy. It is a potential ideal small field imaging
technique that optimally should be used with a “red
flag” method to target image acquisition. The main
goal of endomicroscopy is to distinguish neoplastic
from nonneoplastic tissue in “real time” and thus
provide the potential for decreased number of biop-
sies. However, there are also clear criteria that may
distinguish IM from gastric type metaplasia at the
Ann. N.Y. Acad. Sci. 1232 (2011) 53–75 c© 2011 New York Academy of Sciences. 57
Barrett’s esophagus: endoscopic diagnosis Ishimura et al.
time of endoscopy that may be helpful in the future.
Two different platforms are available: a scope-based
device that is integrated into the distal tip of the
endoscope and a probe-based device that can be in-
serted through a standard endoscope. Both devices
require administration of an intravenous fluores-
cence agent, fluorescein.
In summary, contrast endoscopy appears to be
most practical way to detect islands of IM after abla-
tion. Endomicroscopy has potential but is less prac-
tical and too time consuming for this goal. Acetic
acid chromoendoscopy has goodpotential but is not
widely used.
5. What is the sensitivity–specificity of the
endoscopic diagnosis of BE?
Roy K.H. Wong
Roy.Wong@us.army.mil
This question will be rephrased to ask: “what is
the positive predictive value of diagnosing Barrett’s
esophagus at endoscopy?” This definition would re-
late to endoscopies which reveal tongues or long
columns of columnar appearing epithelium within
the esophagus that when biopsied reveal either
columnar epithelium or intestinal dysplasia.
The PPVwould be calculated by the formula: true
histologically proven BE positives/endoscopically
suspected BE. The PPV would depend on the def-
inition of BE. According to the British Society of
Gastroenterology,7 anyhistologically provencolum-
nar epithelium within the esophagus would be con-
sidered BE, whereas the ACG Guidelines6 define
BE as requiring IM within the columnar appearing
epithelium.
Utilizing these criteria, there would be a much
higher PPV for BE with the British definition. For
LSBE, it would be 100%; whereas for SSBE, it would
probably be greater than 95% with difficulty differ-
entiating a very short segment of BE also known
as cardia IM (CIM), esophagogastric junction spe-
cialized IM (EGJ-SIM), and ultra-short segment BE
from a normal SCJ.
Utilizing the ACG guidelines, the PPV of endo-
scopically identifying BE would vary considerably
depending on the following factors: (1) the number
of biopsies obtained and (2) length of the Barrett’s
epithelium17; whether the biopsies were obtained
from areas of esophagitis or visually uninflamed
columnar epithelium.
Studies byHarrison et al.17 indicate that themore
biopsies obtained, the greater the likelihood of iden-
tifyingBE. For practical purposes, the optimal num-
ber of biopsies that should be taken is eight per pro-
cedure with a likelihood of identifying IM in 67.9%.
If only four biopsies are obtained, 34.7% would be
positive for IM. Another factor that is associated
with a higher yield is the length of the columnar
epithelium.18 As the length of the tongue or col-
umn of columnar epithelium increases, the likeli-
hood of identifying IM will also increase. In histo-
logical studies, the IMwas proximal, locatedmainly
next to the SCJ with fundic and cardia cells noted
Table 2.Positive predictive value of identifying BE with SIM
Author n EGJ-SIM (prevalence) SSBE (PPV) LSBE (PPV)
Winters et al.76 (Gastro) 97 50%
Cameron et al.77 (Gastro) 27 37%
Johnston et al.78 (AJG) 172 7% 9.4% 100%
Weston et al.79 (AJG) 237 48%
Trudguill et al.80 (Gut) 120 18%
Pereira et al.81 (Gut) 75 25% 61.3%
Hackelsberger et al.82 (Gut) 423 13.4% 44% 88%
Eloubeidi et al.18 (AJG) 146 25% 55%
Hirota et al.83 (Gastro) 889 54% 73%
Harrison et al.17 (AJG) 296 Mixed group (1–11 cm, mean = 4
cm) 16 Bx = 100%, 8 Bx =
67.9%, 4 Bx = 34.7%
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in the mid- and proximal portion of the colum-
nar lined esophagus. Finally, biopsies obtained from
esophagitis had a lower likelihood of identifying BE
by 12%.19
The calculated PPV for SSBE ranged from 9.4%
to 61.3% and for LSBE 50% to 100% for LSBE
(Table 2).
6. Is capsule endoscopy an accurate
enough tool for BE screening in clinical
practice?
Lauren B. Gerson
lgerson@stanford.edu
Wireless video capsule endoscopy (VCE) was ap-
proved by the Food and Drug Administration in
2001 as an adjunctive aid for the detection of small
bowel disorders. Because patients ingest the capsule
in the standing position and the small bowel VCE
captures two frames per second, the traditional VCE
oftendoesnot capture imagesof the esophagogastric
junction. Developed in 2004, the esophageal cap-
sule, or PillCam ESO (Given Imaging, Ltd., Duluth,
GA, USA), captures 14 frames per second whereas
the patient ingests the capsule in a supine position
and then gradually resumes the sitting position dur-
ing a 5-minute period.20 Usage of the first genera-
tionPillCamESOdemonstrated excellent sensitivity
and specificity for the detection of erosive esophagi-
tis and BE in a preliminary study of 106 patients
(93 with GERD, 13 with BE).21 However, the results
may have been biased by the usage of a post hoc
adjudication committee and BE was not confirmed
by biopsy. A second blind prospective trial demon-
strated a sensitivity of 67% for BE detection com-
paring PillCam ESO to standard esophagogastro-
duodenoscopy (EGD).22 Using these performance
parameters, two cost-effectiveness models were un-
able to conclude that the usage of esophageal capsule
endoscopy (ECE) was cost-effective in the screening
of BE.23,24 The main reason for these findings were
that the detection rates of BE were modeled to be
70% for ECE compared to 85% with EGD, in ad-
dition to a 50% poor visualization rate of the EGJ,
which would lead to an upper endoscopic examina-
tion and increase the cost of the EGD arm.
A second generation esophageal capsule, ESO-
2, was released by Given Imaging in 2007 with a
30% increase in the frame capture rate from 14 to
18 frames per second, advanced optics with three
lenses instead of one lens, and expansion of field of
view from140◦ to 169◦.25 Tomaximize visualization
of the EGJ and reduce the presence of bubbles, the
standardized ingestionprotocol (SIP)waspublished
by Gralnek et al. and included having the patient
lie on his/her right side during capsule ingestion
while sipping 5–10 ml of water every 30 seconds.25
A subsequent clinical trial in 28 subjects using the
SIP protocol and ESO-2 demonstrated visualization
of the Z-line in 75% of subjects, and sensitivity of
100%with specificity of 74% forBEdetection.26 The
agreement between ESO-2 and EGD for description
of the Z-line was 86% ( = 0.68).
A 2009 meta-analysis27 including nine studies
with 618patients undergoingprimarily thefirst gen-
eration ECE demonstrated a pooled sensitivity and
specificity of ECE for BE detection of 77% and 86%
compared to 78% sensitivity and 90% specificity for
EGD. Usage of SCE in one study demonstrated sen-
sitivity of 78%with specificity of 83%.28 The authors
concluded that upper endoscopy should remain the
preferredmodality in the evaluation of patientswith
suspected BE.
Therefore, although the usage of ECE has been
demonstrated to be an acceptable screening modal-
ity for the presence of esophageal varices,29 it is not
possible in most regions of the United States to ob-
tain insurance authorization in order to perform
an ECE study in a patient for evaluation of GERD
and/or screening for BE. Given the superior perfor-
mance parameters with usage of the ESO-2 and SIP
protocol, however, further clinical studies may be
able to add to the encouraging results from the ini-
tial studyusingESO-2. In addition, further advances
in VCE technology allowing for even better visual-
ization of the Z-line and possible tissue acquisition,
could render the performance parameters of VCE
favorable compared to standard upper endoscopy.
7. Should SCE, allowing controlled
movement within the esophagus, have
better accuracy in the diagnosis of BE?
Francisco C. Ramirez
FRami36715@aol.com
The major drawbacks of the ECE device in its
current form that may affect the accuracy of the
images and thus the diagnosis of an esophageal
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Table 3. Performance characteristics of string capsule
endoscopy (SCE) for the diagnosis of Barrett’s esophagus
when using esophagogastroduodenoscopy (EGD; visual)
and intestinal metaplasia (IM) as the gold standard
Sensitivity Specificity PPV NPV Accuracy
SCE (visual) 78% 89% 86% 83% 84%
EGD (IM) 87% 69% 59% 91% 75%
SCE (IM) 94% 79% 79% 96% 84%
PPV, positive predictive value; NPV, negative predictive
value.
condition, BE in this case, include (1) esophageal
transit time, which often is too short and in about
5% may be too prolonged, but, more importantly,
is unpredictable with reported ranges from 1 to
1,678 sec; (2) the challenge of the Z-line visual-
ization and its relationship to the gastro-esophageal
junction; (3) the potential and frequent interfer-
ence of the images with bubbles and secretions
and the inability to clean the lens(es); and (4)
the “snapshot” phenomenon that refers to the
inherent inability to reexamine any area of inter-
est multiple times and when in doubt. The data re-
garding the performance characteristics of wireless
capsule endoscopy in the diagnosis of BE have been
reported recently in the form of a meta-analysis.32
The pool sensitivity and specificity were found to be
77% and 86%, respectively for all studies analyzed.
The pooled sensitivity and specificity of capsule en-
doscopy when EGD was used as the gold standard
were 78% and 90%, and when IM was used as the
gold standard, were 78% and 73%, respectively (the
low specificity was thought to be the result of a
study published in abstract form only). SCE was de-
signed by attaching a tethering device (composed of
strings, or strings with a sleeve) to the small bowel
or the esophageal capsule devices for circumventing
the drawbacks outlined above and its feasibility ini-
tially tested for BE30 and esophageal varices.31 The
control of the capsule device through strings con-
verts a physiological-dependent into an operator-
dependent procedure. The addition of the real time
viewer makes the procedure easier and more effi-
cient. An additional feature allows its retrieval and,
after discarding the tethering device and steriliza-
tion or high-grade disinfection, to reuse the capsule
and thus render the procedure cost-effective.
The data of SCE of 100 consecutive patients28
referred for screening of BE and when using IM as
the gold standard are summarized in Table 3.
So, going back to the question: should SCE, al-
lowing controlled movement within the esophagus,
have better accuracy in the diagnosis of BE? The an-
swer is not only that it should, but, it does. However,
the data need to be validated.
8. What attitude should be adopted when
there are no visible abnormalities in a
patient?
John David Horwhat
John.david.horwhat@us.army.mil
One can appreciate that the ability to diagnose Bar-
rett’s when encountering a columnar-lined esoph-
agus at endoscopy is not a straightforward task, so
what is meant by “no visible abnormalities?” First,
we must acknowledge that what we see when we
perform endoscopy is greatly influenced by a host
of factors, including our training and the preju-
dices, biases, and experiences that we have had in
our practices (Table 4). Too often, what we see is
Table 4.Comparison of imaging techniques
Modality Availability Cost Ease of use Utility
Indigo carmine +++ + +++ ++/+++
Methylene blue +++ + ++ +/++
Acetic acid +++ + +++ +++
High definition endoscopy ++ ++ +++ +++
Narrow band imaging (zoom) +/++ ++ ++ +++
Autoflourescence imaging + +++ + ++
Trimodal endoscopy + +++ + ++/+++
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what we expect to see, and we can certainly miss
subtle abnormalities if our eyes are not calibrated
or trained to detect them. In fact, what is not visible
or conspicuous to one endoscopist may be a glaring
abnormality to another. One needs only to compare
adenoma detection rates between colonoscopists to
gain anunderstanding of how similar physicians can
achieve different outcomes.
Further, we should acknowledge that looking is
not the same as seeing, and you need to know what
you are looking at. This includes an understand-
ing of the appearance and proper interpretation
of findings at simple white light endoscopy. Very
subtle changes in the surface texture or color may
be overlooked if one fails to clean surface mucus
with proper irrigation, take the time to insufflate
or let the lumen quiet after peristalsis. Just as one
might overlook a flat adenoma in the colon, we
need to be aware for subtleties when examining pa-
tients with a columnar-lined esophagus. Clearly, if
one has the ability to perform surface enhancement
with acetic acid and/or magnify the image, the en-
doscopist must have a complete understanding of,
and ability to, interpret both the normal and abnor-
mal vascular and pit patterns of the mucosa before
stating there are no visible abnormalities.
Next, one must know how best to employ ex-
isting technologies to see the mucosa. We realize
that not all of us currently have or will be able to
justify the purchase of equipment to perform ad-
vanced imaging techniques. And even if we do have
these scopes in our centers, not all of us will have
beenproperly trained in the interpretationof images
taken with narrow band or multiband endoscopy
or the application of red flag technology such as
autofluorescence to avoid high false positive rates.
Certainly, we cannot expect all the world’s Barrett’s
patients to only be treated at centers of excellence
that do have this capability. So what can the rest of
us do?
Indigo carmine, as shown by a multicenter study
of 56 patients, had a sensitivity and specificity in the
83–88% range and negative predicitive value (NPV)
of 98% forHGD.32 A recentmeta-analysis reviewing
workdonewithmethyleneblue concluded that there
is really no significant incremental yield over ran-
dom biopsies for the detection of SIM or dysplasia
with this agent.15 Acetic acid scores favorably in be-
ing cheap, readily available and easy to use. A recent
study from Longcroft-Wheaton et al. demonstrated
a 95.5% sensitivity and a near perfect correlation
with final histology (r = 0.98) when using acetic
acid for guiding targeted biopsies using HR white
light endoscopy.33 HRE is hard to describe by itself
because the bulk of the literature speaks to HR NBI
or HR acetic acid and not merely the incremental
gain of HR compared to standard endoscopy.
To consider narrow band and multiband imag-
ing, we need to acknowledge that the published
work with this technology is almost entirely with
magnificationusing 240 seriesOlympus endoscopes
not available in the United States. With autofluo-
rescence and trimodal endoscopy, we shift toward
modalities that are still very much confined to a
fewcentersof excellence—namelyAmsterdam;Not-
tingham, UK; Jacksonville, Florida; and Rochester,
Minnesota. Evenwithin these centers, there remains
difficulty in finding the best application and in-
terpretation of this technology. Experts from these
centers convened to determine how to reduce false
positives seen with autoflourescence by trying to
determine what endoscopic features were most pre-
dictive of early neoplasia in AF-positive areas. The
best they could accomplishwasmoderate agreement
with a  ranging from 0.49 to 0.56.34 This statement
is not meant to impugn their efforts or the tech-
nology, but merely to show that we are still quite
far away from realizing the best way to employ this
technology.
So, what current guidance can we take from the
experts? A recent multicenter study has demon-
strated that trimodal imaging is still unable to be
considered superior to random 4QB taken with
standard endoscopy with regard to detection of le-
sions.35 This study, from the group of four cen-
ters of excellence previously mentioned, used an
HR trimodal Olympus system versus standard en-
doscopy with an Olympus 140 or 160 series in-
strument. Although the targeted yield of endoscopy
was improved with autofluorescence, the problem
of false positives remained, and even using NBI to
try and reduce the false positives was problematic
in that 17% of HGD and cancer lesions were er-
roneously classified as nonsuspicious by NBI. In
addition, a study from the Weisbaden, Germany
group studied high- and low-risk Barrett’s groups
with HR acetic acid targeted biopsies versus stan-
dard 4QB.36 Interestingly, although the targeted ex-
ams were superior, their final statement was that
they do not advocate abandoning 4QB outside of
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a setting such as exists within their highly special-
ized centerwith rigorousquality controlmeasures in
place.
In summary, the attitude that should be taken
for the patient with no visible abnormalities is one
of high-quality white light endoscopy. Ideally, we
would all like to have HR as our standard instru-
ments, but while we wait for this, we should at least
aim to enhance our knowledge of the interpretation
of normal—at a minimum, teaching ourselves and
our trainees what the normal and abnormal pit and
vascular patterns look like. One should learn how to
optimally use the technology you currently have, but
if not fortunate enough to have enhanced imaging
capability, surface enhancement with cheap, readily
available materials like acetic acid can be used. The
current evidence shows that autofluorescence-based
strategies are still too expensive, not widely avail-
able, nonstandardized, and even in expert hands
suffer from an unacceptably high false positive rate
to make it viable at this time. That leaves the major-
ity of us in the United States with learning how to
interpret unmagnified NBI images, learning how to
better appreciate subtleties for targeted biopsies and
remembering to always, always, always, take four-
quadrant random biopsies to make sure we do not
miss the forest for the trees.
9. What can be expected from magnifying
endoscopy associated with NBI for the
detection of SIM in BE?
Charles J. Lightdale
cjl18@columbia.edu
High-resolution white light endoscopy
Modern endoscopes use HR digital systems using
charge-coupled devices (CCD) in the endoscope tip
with greater than 1,000,000 pixels compared to the
300,000 of prior standard endoscopes. Combined
with high-definition television monitors with 1,080
scanning lines compared with the standard analog
576 lines, HRE provides an extraordinary clear and
detailed moving image.37
Magnification endoscopy
HREs also are generally equipped with an elec-
tronic zoom system that provides some magnifi-
cation, routinely to 1.5×. However, magnification
endoscopes are available using optical zoom sys-
tem with mechanically adjusted lens systems for
much greater magnification without loss of reso-
lution. The difficulty is that focal length decreases
with increasing magnification, which can make it
difficult to keep images in focus even with the use
of transparent endoscope caps to stabilize the target
tissue. The maximal efficiency of these systems is in
combination with chromoendoscopy.38
Optical chromoendoscopy
Optical chromoendoscopy sometimes called virtual
image enhanced endoscopyprovides an instant “vir-
tual” contrast applied with the push of a button.
Thus, optical chromoendoscopy offers a fast clean
alternative to dye-spraying or physical chromoen-
doscopy. The Olympus system called NBI uses fil-
tered light for this effect, whereas other systems use
digital postprocessing.37,38
Narrow band imaging
In this system, filters alter the illuminating light,
decreasing the red component, and allowing only
narrow bands of blue (390–445 nm) and green light
(530–550 nm) to illuminate the mucosal surface.
These short wavelengths penetrate the mucosa only
superficially, improving the view of mucosal surface
patterns and highlighting vasculature.15
NBI and magnification in BE
Nondysplastic specialized IM (SIM) under NBI and
magnification shows a regular tubular, ridged, or
villous pattern with branching elongated vessels.
Norimura et al. recently described an appearance
of characteristic “light blue crests” in a beautifully
illustrated article.39 Mannath et al. recently pub-
lished a meta-analysis using NBI for detection of
SIM, finding a high sensitivity of 0.95 in six pooled
studies, whereas specificity was low at 0.65.40 Mag-
nification with NBI has improved visualization of
the squamo-columnar junction (Z-line) and small
tongues of SIM in very short BE, and has helped
detect small islands of SIM for biopsy or ablation.
10. Can association of NBI with HRE lead
to a change in the current practice of
random biopsies in Barrett’s patients?
Kenneth R. DeVault
devault.kenneth@mayo.edu
In the United States, the diagnosis of BE requires
the endoscopic appearance of columnar mucosa
extending into the tubular esophagus along with
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histological confirmation of specialized columnar
epithelium (SCE) in biopsies from that mucosa. On
the other hand, many patients with the appearance
of short segment BE, and even some with what ap-
pears to be long segment BE, will not have SCE on
randombiopsies.41Whether this is due to thepatient
not having BE or whether it represents sampling er-
ror has not been clear. In addition, in regards to
finding dysplasia, some patients will have dysplasia
on one endoscopy and not on subsequent exams,6
which also could be due to sampling error.
Among the severalmethods of enhancing themu-
cosal view, NBI is simple, widely available, and may
improve the yield of esophageal biopsies for both
SCE and dysplasia.42 Based on these and other data,
we would suggest that NBI does increase the yield of
SCE over random biopsies, but would still do a sim-
ilar number of biopsies as have been suggested for
nontargeted exams (at least four biopsies for each 2
cm of Barrett’s appearance).
Difficulties in finding dysplasia in a patient with
BE remains a challenging proposition. A study
where patients underwent both standard resolution
endoscopy and HR/NBI was recently reported by
Wolfsen et al.43 In that study, NBI and standard en-
doscopy found the same grade of dysplasia in 82%
of patients, but a higher grade of dysplasiawas noted
18%of patients with combinedHR/NBI. In no cases
did standard endoscopy find a higher grade of dys-
plasia than HR/NBI and there were less biopsies re-
quired in the HR/NBI study. This study has resulted
in our center suggesting a careful HR/NBI evalu-
ation of all BE patients with targeted biopsies. We
still add additional random biopsies in most cases
to equal at least the total minimal number suggested
in the so-called Seattle protocol (four-quadrants for
every 1 cm).
In summary, NBI has changed the approach to
Barrett’s in specialized centers in that it allows a
more detailed view and mapping of the affected
segment. Whether this change in practice will be
widely adopted remains to be seen.
11. Can NBI be considered a tool for
routine clinical practice?
Giancarlo Freschi, Antonio Taddei, Maria Novella
Ringressi, Vega Ceccherini, Francesca Castiglione,
Duccio Rossi Degl’Innocenti, and Paolo Bechi
giancarlo.freschi@unifi.it
When NBI was introduced, endoscopists were fas-
cinated by the possibility of detecting the pathol-
ogy in real time by simply pressing a switch, such
as taking a picture. In 2006, Sharma et al.44 pub-
lished an editorial with a compelling title, “Bar-
rett’s esophagus—see more, biopsy less!” The ques-
tion in the title obviously concerns the diagnosis of
GERD, and its pathological consequences, innormal
endoscopy units rather than highly specialized BE
centers.
To compare our performances to the data pre-
sented in literature and to answer the question,
we analyzed 200 consecutive EGDS performed in
GERD patients and evaluated the effectiveness of
NBI with respect to:
• recognition of esophagitis cases (distinguishing
NERD from true esophagitis);
• detection of Barrett’s metaplasia; and
• detection of esophageal dysplasia (low or high
grade) or adenocarcinoma. All the images were
correlated with histology results.
Concerning recognition of esophagitis, previous
studies have found that fewer than40%ofGERDpa-
tients have positive upper endoscopy findings. The
utility of the NBI magnification system as a diag-
nostic tool for GERD has been explored increas-
ingly focusing whether the changes on observed
mucosal and vascular patterns correlate with his-
tology. Sharma and Fock found that a significantly
higher proportion of GERD patients had changes
easy to observe using NBI, such as:
• the number, dilation, and tortuosity of intra-
papillary capillary loops (IPCL);
• the presence of microerosions;
• an increase in vascularity at the SCJ; and
• columnar islands in distal esophagus.
Our experience of using NBI to diagnose ero-
sive esophagitis, observing the parameters pre-
viously described, in 162 consecutive EGDS
performed on patients with clinical symptoms in-
dicating GERD, reveals that the improvement in di-
agnosis of esophagitis after NBI observation com-
pared with simply white light observation was of
nearly 25% (P < 0.01). However, to date, there is
still a need for prospective randomized controlled
trials to validate the mucosal and vascular patterns
seen in the above studies.
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Detection of Barrett’s metaplasia
Theoretically, NBI has the advantage of allowing the
endoscopist to make an in vivo diagnosis, without
the need for random biopsies. In recent years, sev-
eral studies44–46 have led to different classifications
of patterns suggesting IM. These studies have de-
scribed and classified patterns of mucosal and vas-
cular morphology in BE based on magnification
endoscopy associated with NBI, focusing on the
recognition of IM in columnar-lined esopha-
gus. Unfortunately, the classifications proposed in
these studies consist in many different categories
hampering implementation of NBI in daily prac-
tice. Some classifications use up to six categories
for mucosal patterns, and others also require the
description of the vascular pattern in multiple cat-
egories. In other words, although the available re-
sults from the studies describing the changes seen
under NBI endoscopy for BE appear promising,
the lack of a sufficiently validated and standard-
ized classification scheme is one of the main lim-
itations to the diffusion of the use of NBI for
detecting BE and dysplasia. To improve the prac-
ticality of NBI in BE, some authors have proposed
a more simplified classification in which only the
(ir)regularity of the mucosal and vascular patterns
are described. Our group used this simple classifi-
cation for detection of BM in clinical practice. We
had 89 NBI images for 38 patients in areas indicat-
ing columnar metaplasia from white light observa-
tion. The results were a good sensitivity (90%), but
only 78% for specificity with 83% for PPV (Fig. 2,
left).
Diagnosis of dysplasia or neoplasia
The current practice of endoscopic surveillance
in patients with BE has limitations. Biopsies are
performed randomly and sample only 4% to 6%
of the surface area of the metaplastic epithelium.
Preliminary results from a randomized, controlled
crossover showed that, as compared with a strategy
of performing 4QB every 2 cm, the use of targeted
biopsies with narrow-band imaging identified sim-
ilar proportions of patients with metaplastic lesions
(85% with each procedure) and neoplastic lesions
(71% with targeted biopsies and 55% with 4QB,
but involved fewer biopsy specimens per procedure
[3.6 versus 7.6, P < 0.001]).44,51 But this is not the
case when identifying dysplasia or carcinoma in BE
patients through a simple endoscopy procedure, so
that many experts conclude that it is questionable
whether magnification endoscopy in combination
with NBI at this time is ready to replace histological
sampling for differentiating dysplastic from non-
dysplastic Barrett’s tissues. Also, for the detection
of early Barrett’s neoplasia, only two studies with
conflicting results have investigated NBI for this in-
dication. Both studies, however, have considerable
drawbacks that may impede their validity. Our lim-
ited experience confirms the uncertainty concern-
ing NBI’s potential in diagnosis of dysplasia (sen-
sibility: 80%; specificity: 78%; PPV: 60%; Fig. 2,
right).
Conclusion
The available studies regarding the use of NBI in
detecting GERD, SIM, and dysplasia or neoplasia
appears promising and, presently, NBI is used as an
adjunct to conventional white light endoscopy for
targeted investigation of suspicious areas.
The main limitations of the NBI system include:
• the learning curve associated with the new tech-
nology (the reported studies have been per-
formed in very high-risk BE patients by en-
doscopists very experienced in the care of such
patients, but thewidespread applicability of this
technique is unknown);
• the lack of sufficiently validated and standard-
ized classification schemes for the NBI patterns
observed in various conditions; and
Figure 2. Personal data: results in NBI endoscopic detection of Barrett’s metaplasia.
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• the limited number of randomized controlled
trials investigating NBI compared with conven-
tional white light endoscopy.
Further large-scale studies are also required to
address these limitations before NBI can be rec-
ommended as a primary method of screening
or follow-up for Barrett’s esophagus in routine
practice.
12. What is the sensitivity–specificity of
balloon cytology in detecting low-grade
dysplasia?
Helen H. Wang
hwang@bidmc.harvard.edu
Although it is a wonderful idea to screen with
nonendoscopic balloon cytology for dysplasia in
patients with BE, data on this subject are lim-
ited by the fact that most studies of balloon cytol-
ogy were conducted in high-risk regions of China
for esophageal squamous cell carcinoma. In addi-
tion, the diagnosis of low-grade dysplasia in BE
is controversial even on histology as cases are of-
ten overdiagnosed and its prevalence is under-
estimated.47
With histology as the gold standard, balloon
cytology has been found to have low sensitiv-
ity (20–55%), but reasonable to high specificity
(66–100%).48–50 The higher sensitivity results were
based on studies that involved using a new me-
chanical balloon for 50% of the study subjects,
which apparently increased cellular yield and thus
sensitivity.49
Despite its low sensitivity when compared to his-
tology, based on an outcome/follow-up study,51 bal-
loon cytology was useful for risk stratification of
esophageal cancer, including glandular lesions. An-
cillary molecular studies on cytologic specimens
have been investigated to determine its value. When
appropriate probes, such as for 8q24 (C-MYC), 9p21
(P16), 17q12 (HER2), and 20q13, were used, fluo-
rescence in situ hybridization (FISH) indeed signif-
icantly improved the sensitivity in the detection of
dysplasia in patients with BE.52
In summary, balloon cytology has low sensitivity
but high specificity to detect low-grade dysplasia in
BE. New types of mechanical balloons and ancil-
lary molecular study may improve the sensitivity of
balloon cytology.
13. Despite the promising value of FC in
detecting aneuploidy of G2/tetraploidy on
cytological specimens, cost, and restricted
availability of this technique represent
limitation of its wide clinical use
Qin Huang
Qin.huang@va.gov
FC uses laser technology to measure the DNA con-
tent of cells in suspension that pass through a
laser beam. The reliability of this method for de-
tection of DNA aneuploidy associated with Bar-
rett’s esophagus and Barrett’s esophageal adeno-
carcinoma (BEA) has been questioned for its low
sensitivity and poor reproducibility. In biopsies of
Barrett’s esophagus, DNA aneuploidy detected by
FC was considered to be a better marker than his-
tology for assessing prognosis by some investiga-
tors,53 a conclusion that could not be confirmed by
others.54
In BEA, conventional karyotyping and compar-
ative genomic hybridization studies have showed
that aneuploidy with widespread chromosomal
and DNA abnormalities are present in almost all
BEA tumors. However, previous reports using FC
have shown that up to 31% of BEA cases were
diploid and negative for DNA aneuploidy.53–56 For
example, in one recent study by standard FC in
archival formalin-fixed, paraffin-embedded resec-
tion tissues with histopathology-confirmed 42 BEA
tumors,55 FC detected DNA aneuploidy in only
71% of cases; the remaining 29% were diploid and
negative for aneuploidy. In the cases with DNA
aneuploidy, FC showed the qualitative evidence of
DNA aneuploidy and failed to identify severe ane-
uploidy and high DNA heterogeneity fractions in
32% of cases and 9N exceeding rates in 51%. These
parameters are the markers for high risk of cancer
progression and were missed by FC. In addition to
the low sensitivity ofDNAaneuploidy detection and
failure of identification of high-risk cases with DNA
ploidy abnormalities, the reproducible rate of DNA
ploidy by FC in different parts of the same tumor
was only 50%.55 This apparent sampling error is not
acceptable clinically.
This poor reliability of FC in detection of DNA
aneuploidy in BEA results from intrinsic technical
errors due to inclusion of all cells in suspension
into calculation of DNA content. Another source
of errors is biopsy sampling, a problem associated
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with all biopsies. By FC, the cell suspension sam-
ple should have at least 20% of neoplastic cells
with a total number of over 10,000 cells for an
effective analysis.56 This requirement may not be
practical for FC to meet in a small biopsy tissue
sample.
In conclusion, recent data indicate that DNA
ploidy analysis by FC in a biopsy or resection tissue
specimen is qualitative, insensitive, poorly repro-
ducible, and lacks quantitative information such as
heterogeneity index and 9N exceeding fractions for
disease progression. These shortcomings along with
technical flaws andhigh cost prevent its wide clinical
applications. However, DNA ploidy determination
appears to be a powerful method for determination
of cancer risk and progression in Barrett esophagus-
related disease and can be carried out by improved
image cytometry that is easier to use and more reli-
able than FC.57
14. What is unstable aneuploidy? Is it a
marker for neoplastic progression?
Andrew M. Bellizzi
abellizzi@partners.org
What is aneuploidy?
Aneuploidy, most simply put, refers to an abnormal
numberof chromosomes.Theaneuploidphenotype
reflects genomic, and more specifically chromoso-
mal, instability and is commonly observed across
the broad range of human tumors. Although the
proximate cause of aneuploidy is abnormal mi-
totic segregation, the ultimate causes are poorly
understood. In addition to being a biomarker for
neoplastic progression, aneuploidy may be mech-
anistically involved, by increasing the dosage of
oncogenes, decreasing the dosage of tumor suppres-
sor genes, and by serving as a source of genetic diver-
sity on which natural selection acts.58 Aneuploidy is
assessed by DNA FC and image cytometry on tissue
sections.
Aneuploidy and neoplastic progression in BE
Aneuploidy represents one of the best-studied and
most powerful predictors of neoplastic progression
in BE. Reid et al. (Seattle Barrett’s Esophagus Re-
search Program) found that 9/13 (69%) patients
with aneuploid or increased G2/tertraploid popu-
lations on initial FC developed high-grade dyspla-
sia (HGD) or adenocarcinoma (AdCa) on follow
up (mean 34 months). This included two patients
with biopsies initially negative for dysplasia and five
patients in the indefinite/low-grade dysplasia cate-
gory. In contrast, 0/49 (0%) patients without a flow
abnormality progressed to HGD or AdCa.53 In a
larger study from the same group, constituting their
experience with a prospective surveillance cohort of
307 patients, 42 of whom developed cancer, Rabi-
novitch et al. reported the relative risk (RR) of ane-
uploidy for the development of AdCa at 5.9. They
also showed that the distribution of aneuploidies is
bimodal, with “triploid,” and “near-diploid” aneu-
ploidies. “Triploid” aneuploidy, which they defined
as a DNA content >2.7N, is an especially high-risk
lesion with an RR of 9.5.59
What is unstable aneuploidy?
The term “unstable aneuploidy” is ill-defined, and
in fact, a PubMed search for the terms “unstable
aneuploidy” and either “esophagus” or “Barrett’s”
returns three results, only one of which actually uses
the term “unstable aneuploidy” in the manuscript
text. Although Yu et al. do not formally define “un-
stable aneuploidy,” they refer to the “appearance
of newer clones of severer aneuploidy” and state
that “increased scatter of cells, including elevation
of the 5N exceeding fraction may represent unstable
aneuploidy.” They report the results of high-fidelity
DNA histograms (image cytometry on formalin-
fixed, paraffin-embedded tissue sections) in nor-
mal controls (nl), BE, negative for dysplasia (neg),
low-grade dysplasia (LGD), HGD, and AdCa. Data
for each case include ploidy, heterogeneity index
(a measure of the “scatter of cells”), and 5N ex-
ceeding fraction. They found “markedly elevated”
heterogeneity index values and 5N exceeding frac-
tions >5% in 0% of nl, 5% of neg, 32% of
LGD, 50% of HGD, and 88% of AdCa. Interest-
ingly, 69% of neg cases demonstrated at least mild
aneuploidy.60
Is unstable aneuploidy a marker of neoplastic
progression?
Aneuploidy is common in BE and can be seen in
cases even without dysplasia. It would be of inter-
est to learn the follow up on the cases in the Yu
et al. study negative for dysplasia but with “severe”
DNA content abnormalities. From the Seattle Bar-
rett’s Cohort, it is clear that aneuploidy is a marker
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for neoplastic progression and that not all aneuploi-
dies confer the same risk. Although the concept of
“unstable aneuploidy” is ill-defined, it can be con-
ceivedof as “progressive aneuploidy”or “aneuploidy
conferring increased risk.” Yu et al.’s cross-sectional
study was not positioned to answer the earlier ques-
tion, which remains a testable hypothesis.
15. How should extent of dysplasia be
histologically defined? How should
precise distinction between “focal” and
“diffuse” dysplasia be made?
Mikhail Lisovsky and Amitabh Srivastava
Mikhail.Lisovsky@Hitchcock.org
Detection of dysplasia in BE is the current gold stan-
dard for identification of patients at high-risk for
progression to esophageal adenocarcinoma (EA).
However, the natural history of BE patients with
low-grade dysplasia (LGD) and high-grade dyspla-
sia (HGD) remains uncertain and the individual
risk of progression to EA is difficult to quantify.
Extent of dysplasia may correlate with the risk of
progression to EA, but testing of this hypothesis
is compounded by the absence of a uniformly ac-
cepted method for evaluation of the extent of dys-
plasia. Any proposed method for measuring extent
of dysplasia in BE must be objective and repro-
ducible, inorder for it tobe validated across different
studies, and be easily applicable in routine clinical
practice.
Extent of dysplasia in BE as a risk factor for EA
has been evaluated in only a few studies, thus far,
using variable definitions.61–63 The study by But-
tar et al.61 defined focal HGD as one focus of ≤5
dysplastic crypts in one fragment and diffuse HGD
as ≥5 dysplastic crypts in one fragment or more
than one fragment with HGD.61 The primary end-
point was a histologic diagnosis of EA on follow-up.
Diffuse HGD had a 3.5-fold increase in the risk of
progression toEAcompared to focalHGD,whenad-
justed for endoscopic nodularity. Endoscopic nodu-
larity was present in 34% of diffuse HGD, only 6%
of focal HGD and was associated with a 2.5 times
higher risk of EA when adjusted for extent of dys-
plasia. Thus, extent of HGD and endoscopic nodu-
larity were both independent predictors of progres-
sion to EA. Not all HGD patients were treated with
esophagectomy in this study and, therefore, the pos-
sibility of undiagnosed EA could not be completely
ruled out.61
In 2003, Dar et al. studied 42 patients treated
with esophagectomy for a diagnosis ofHGD.62 They
defined focal HGD as dysplasia present at one level
and diffuse HGD as dysplasia present at more than
one level of the BE segment.62 The extent of HGD,
as defined by their own criteria, and by those of
Buttar et al., did not predict presence of EA in the
esophagectomy specimen.61,62
Extent of both LGD and HGD as a predictor of
progression to EA was analyzed in a more recent
study by Srivastava et al.63 All biopsies were scored
for the total number of crypts and the total num-
ber of crypts with LGD or HGD which provided
a measure of percentage of dysplastic crypts with
LGD or HGD in each biopsy. The primary end-
point of this retrospective longitudinal study was a
histologic diagnosis of EA. The patients who pro-
gressed to cancer had a significantly higher mean
percentage of total dysplastic crypts and crypts with
LGD but not HGD. The authors also defined fo-
cal dysplasia as dysplasia present in one fragment,
and diffuse dysplasia as dysplasia present in more
than one fragment, regardless of the level of the
BE segment. Using this definition, diffuse LGD or
combined LGD and HGD was significantly associ-
ated with progression to EA. The focal and diffuse
definitions of Buttar et al. and Dar et al., when ap-
plied to this data set, did not predict progression
to EA.
In view of the conflicting data discussed earlier,
an objective and standardized approach to evaluate
the extent of dysplasia is needed. We favor aban-
doning the use of “focal” and “diffuse” dysplasia
to assess extent of dysplasia because any proposed
definition will be arbitrary. We propose that the ex-
tent of dysplasia be evaluated using a four part ap-
proach that will allow a more objective assessment
of extent of dysplasia in patients with BE: (1) stud-
ies evaluating extent of dysplasia as a predictor of
progression to EA should report the number of
biopsies obtained from flat mucosa and those taken
from areas of endoscopic abnormality to avoid
a sampling bias. Estimation of dysplasia extent
should be performed and reported separately for
flat mucosa and endoscopic abnormality. (2) When
only a single biopsy fragment is involved with
dysplasia, the number and percentage of crypts
with LGD, HGD, or combined LGD and HGD
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should be provided. (3) If more than one frag-
ment from the same level is positive for dysplasia,
then the total number of fragments, the number of
fragments with dysplasia, and the grade(s) of dys-
plasia should be recorded. (4) Finally, the num-
ber of levels in a BE segment positive for dys-
plasia and the grade(s) of dysplasia should be
recorded.
Using this approach, thedata across relevant stud-
ies on this subject can be easily compared and allow
correlation of accurately defined groups of extent of
dysplasia with risk of progression to EA. This may
eventually lead to detection of a threshold that en-
ables meaningful stratification of BE patients with
dysplasia into those at low and high risk of progres-
sion to EA.
16. What are the differences between the
main categorization systems used for
grading dysplasia in BE?
Robert H. Ridddell
rriddell@mtsinai.on.ca
It needs to be appreciated that these two systems
were “invented” for completely different reasons.
The IBD-C was created in the early 1980s to try
to resolve numerous issues causing problems at
that time.64 These included (1) no definition or
criteria for dysplasia; (2) three grades of dyspla-
sia in general use—mild, moderate, and severe,
which may or may not include carcinoma in situ
(CIS); (3) ambiguity of terminology in use be-
cause terms such as “dysplasia,” “mild dysplasia,”
and “atypia” were all used for both reactive and
neoplastic changes; (4) the clinical implications of
these diagnoses were unclear; and (5) for all of these
reasons there could be no attempt to determine
reproducibility.
The resulting classification did the following: dys-
plasia was defined as an unequivocally neoplastic
proliferation and any grade could give rise directly
to an invasive carcinoma. The classification system
included four categories, eachofwhichalsohadclin-
ical implications that, until recently, also applied to
BE, as follows:
• Negative: continue surveillance;
• Indefinite: early rebiopsy following Rx if
possible;
• LGD: early rebiopsy or consider colectomy; and
• HGD: consider colectomy.
Note: There were only two grades of dysplasia,
so that “mild,” “moderate,” and “severe” dysplasia
ceased to exist, and were (and still are) now obsolete
terms. It was also found to be fairly reproducible,
especially when no or HGD were present.
The aim of the VCS was to develop a com-
mon worldwide terminology for gastrointestinal
epithelial neoplasia. In practice, this expanded to
become a classification and grading system for
both dysplasia (noninvasive) and invasive neopla-
sia, whereas the concepts, principles, and defini-
tion of dysplasia system were accepted from the
1983 publication. Its objectives were to minimize
the widely recognized discrepancies in interpreta-
tion ofmorphologic dysplasia betweenWestern and
Japanese pathologists; and to reach a uniform con-
sensus on the nomenclature of neoplastic precursor
lesions.
The resulting classification system was as fol-
lows65 with the IBD-C shown on the right.
Category 1: Negative for
neoplasia/dysplasia
Negative
Category 2: Indefinite for
neoplasia/dysplasia
Indefinite
Category 3: Noninvasive low-grade
neoplasia
(low-grade
adenoma/dysplasia)
Low grade
Category 4: Noninvasive high-grade
neoplasia
High grade
4.1: High-grade
adenoma/dysplasia
4.2: Noninvasive carcinoma
(carcinoma in situ)∗
4.3: Suspicion of invasive
carcinoma
Category 5: Invasive neoplasia
5.1: Intramucosal carcinoma
(lamina propria)
5.2: Submucosal carcinoma or
beyond
In practice, there was a minor change in termi-
nology, and the addition of several categories after
high-grade dysplasia.
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17. What can be expected from the
endoscopic detection of dysplasia using
5-ALA sensitization and illumination with
blue light?
Lawrence F. Johnson
lfjmd@bellsouth.net
The compound 5-amino levulinic acid (5-ALA) is a
prodrug that may be given orally or topically and is
absorbed by the mucosa and metabolized to proto-
porphyrin IX (PpIX), a photo sensitizer. Because the
degradation enzyme of PpIX, ferrochelatase, is de-
ficient in dysplastic tissue, PpIX accumulates, and
in blue light fluoresces. In turn, this fluorescence
provides the endoscopist an opportunity to visually
distinguish dysplastic tissue/adenocarcinoma with
its intense fluorescence from that of normal tissue,
and thereby, to perform target biopsies as opposed
to random 4QB taken every one or two centime-
ters.66–68
This special fluorescent illumination was accom-
plished through a standard endoscope. To excite the
PpIX, a filtered xenon lamp using blue light at a
Figure 3. Sensitivity, specificity, andpositive andnegative pre-
dictive values determined from the presence or absence of dys-
plasia in fluorescent or nonfluorescent tissue using different
doses of 5-ALA (from Endlicher et al.66).
wave length of (380–460 nm) was connected to the
scope, and in turn the ocular part of the scope was
connected to a camera controller that sent either an
image with white or the blue excitation light to the
video monitor.68
The proof of the above concept was established by
Endligher et al.,66 who looked at sensitivity, speci-
ficity, and positive and negative predictive values
determined from the presence or absence of dys-
plasia in fluorescent or nonfluorescent tissue using
different doses of 5-ALA (Fig. 3). As shown, sen-
sitivity occurred in the 80–100% range with the
10 and 20 mg/kg, dose respectively, and specificity
much less (56% and 51%, respectively). However,
thenegativepredictive valuewashigh inbothgroups
(90–100%, respectively). That is, if the mucosa was
fluorescence-negative, no dysplasia was found—an
endoscopically helpful and clinically relevant find-
ing in the surveillance of patients with BE. Based
on these results, the authors recommended a ran-
domized prospective clinical trial to demonstrate
the benefit of endoscopic FED compared to the
standard technique of white light endoscopy with
Figure 4. Comparable sensitivity, specificity, and positive and
negative values were obtained for dysplasia found in fluoresc-
ing and nonfluorescing mucosal areas as reported by Endlicher
et al.66
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Figure 5.
random biopsies taken every 1–2 cm in four quad-
rants in patients with BE.
The above proposed randomized clinical trial was
completed and published by Stepinac et al.68 In their
study involving 28 patients, the authors used en-
doscopic fluorescence with 5-ALA to target biop-
sies for dysplasia and compare them to those ob-
tained randomly using white light (four quadrants
every 1 cm). Again, comparable sensitivity, speci-
ficity, andpositive andnegative valueswereobtained
for dysplasia found in fluorescing and nonfluoresc-
ing mucosal areas as reported by Endlicher et al.66
(Fig. 4). Most importantly, in the comparison be-
tween 4QB obtained every 1 cm and those that used
endoscopic FED, both techniques gave comparable
diagnostic accuracy (Fig. 5). However, endoscopic
FED achieved that result with only 81 biopsies as
opposed to 531 for the conventional white light
technique that took random biopsies from four-
quadrants every 1 cm.68
Wanting to eliminate the human eye from qual-
itatively determining fluorescence versus nonfluo-
rescence, Bland et al.2 used a laser spectrograph sys-
tem that measured fluorescence intensity at 635 nm
and compared both the presence or absence of dys-
plasia and fluorescence intensity from the mucosa
immediately before the biopsies were obtained. As
expected, high-grade dysplasia had protoporphyrin
fluorescence intensity significantly greater than that
found in non-dysplastic Barrett’s epithelium. In-
terestingly, sometimes nodular dysplastic mucosa
sometimes had less PpIXfluorescence intensity than
the surrounding mucosa with high-grade dyspla-
sia. This inconsistency in detection was overcome
by establishing a fluorescence intensity ratio of 635
nm/480 nm, which permitted nodular high-grade
dysplasia to be differentiated from non-dysplastic
tissue with 100% sensitivity and specificity.
In summary, PpIX fluorescence appears useful
for identifying areas of high-grade dysplasia so that
target biopsies might be obtained in patients with
BE. In support of this assertion, endoscopic FED
gives a comparable result compared to that obtained
with four-quadrants biopsies taken every 1 cm;
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however, with fewer biopsies, and, by implication,
less time.
18. What is the technique that allows for
best selection of biopsies and endoscopic
diagnosis of dysplasia?
Michael D. Saunders
mds@u.washington.edu
Current recommended endoscopic surveillance of
BE using the Seattle protocol, 4QB taken every
1–2 cm of the Barrett’s segment has limitations.
These include difficulty in visualizing early neo-
plastic lesions with standard white light endoscopy,
that random biopsies may sample on approximately
5% of the Barrett’s mucosa, and that the dysplasia
can have a patchy and focal distribution.69 These
limitations have ignited a search for an adjunctive
imaging tool to detect and target areas of dys-
plasia. Ideally, this tool or technique would reli-
ably detect early neoplasia, decrease the already low
pretest probability of dysplasia, and, in the absence
of neoplasia, enable risk stratification comparable
to current histology (i.e., no dysplasia versus low
grade).69 To date, no technique has fulfilled these
ideal criteria and, therefore, cannot yet replace the
need for random 4QB. Advanced imaging tech-
niques that have been evaluated for the detection
of Barrett’s dysplasia are summarized below with
their respective advantages and current limitations
(Table 5).
NBI and CLE have been shown to be more ac-
curate than random biopsies, requiring fewer to-
tal biopsies, in detecting and targeting dysplasia in
high-risk patients (those with known or suspected
dysplasia).70,71 However, the overall yield of dyspla-
sia per patient is not changed. Furthermore, the sen-
sitivity of these techniques is decreased in patients
at lower risk for dysplasia, who are the majority of
Barrett’s patients.70
Endoscopic trimodal imaging (ETMI),56,71,75
which includes HRE, autofluorescence (AF), and
NBI has been recently compared to standard white
light endoscopy with random 4QB in high-risk pa-
tients with suspected early Barrett’s cancer and no
endoscopically visible abnormality.72 No significant
difference was observed in overall yield per patient
of dysplasia. AF imaging improved targeted detec-
tion of early Barrett’s cancer compared to standard
endoscopy. NBI decreased false positives but was
associated with a false negative rate of 17%. Simi-
lar results were seen in a separate community-based
study involving intermediate risk patients.73
Summary
HREhas likely become the default standard imaging
technique for best selection of biopsies and endo-
scopic diagnosis of dysplasia. ETMI (AFI) and CLE
improve the targeted detection of dysplasia in high-
risk patients. However, no current technique can
Table 5.Advanced imaging techniques for detection of dysplasia in Barrett’s esophagus
Imaging technique Comment
High-resolution, white-light endoscopy (HRE) • Becoming the standard
Narrow band imaging (NBI) • Yield similar to routine biopsies but with fewer biopsies
• Difficulty with pattern recognition
Autofluorescence imaging (AFI) • Improves detection of dysplasia
• High false positive rates
Endoscopic trimodal imaging (high resolution
endoscopy, autofluorescence, NBI)
• Improves targeted detection of dysplasia in high-risk patients
Confocal laser endomicroscopy (CLE) • In vivo imaging with subcellular resolution of focal areas
• Image interpretation
Magnification endoscopy • No comparisons with standard endoscopy
• Tedious to use
Chomoendoscopy • Varying results in RCTs
• Lack of standardization of technique
Adapted from Sharma et al.2
Ann. N.Y. Acad. Sci. 1232 (2011) 53–75 c© 2011 New York Academy of Sciences. 71
Barrett’s esophagus: endoscopic diagnosis Ishimura et al.
at this time replace random 4QB, particularly in
low-to-intermediate risk patients, for detection of
dysplasia.
19. What are the criteria to differentiate
inflammatory or regenerative changes
from dysplasia?
Ram Chuttani
rchuttan@bidmc.harvard.edu
Key issues
• Awide spectrumof atypia exists in patientswith
Barrett’s and persistent reflux.
• Regenerative changes may be extreme, espe-
cially in mucosa adjacent to the neo-SCJ or in
areas of active inflammation and ulceration.
• These changesmay lead to overdiagnosis of dys-
plasia.74,75
What is seen pathologically in inflammation?
• Cytologic features of inflammation and
preservation of crypt architecture. In severe
inflammation—crypt budding, branching, at-
rophy, crowding, distortion, or even cystic
changes may be seen.
• There may be nuclear stratification particularly
at the bases of crypts, but occasionally also at
the surface.
Inflammation versus dysplasia
• Regenerating cells contain nuclei with smooth
membranes, normal nuclear/cytoplasmic ratio,
and variable number of normal mitosis.
• Dysplastic cells show nuclear pleomorphism,
loss of cell polarity, andmarkedly increased nu-
clear/cytoplasmic ratio.
• Regenerating cells contain nuclei with smooth
membranes, normal nuclear/cytoplasmic ratio,
and variable number of normal mitosis.
• Dysplastic cells show nuclear pleomorphism,
loss of cell polarity, andmarkedly increased nu-
clear/cytoplasmic ratio.
How to differentiate inflammation from
dysplasia?
• Although in inflammation, some changes of in-
creased nuclear/cytoplasmic ratio, hyperchro-
macity, and slight loss of polarity and pleomor-
phism may be present, tufting of surface cells
helps distinguish from dysplasia.
• In inflammation, goblet cells, both normal and
dystrophic, are common.
• In inflammation, cytoplasmic mucin may be
depleted but the crypt cells show a progressive
increase in mucin close to or at the luminal
surface.
• The surfacematuration is exhibitedbypreserva-
tion of nuclear/cytoplasmic ratio and decrease
in nuclear stratification in the upper level of the
crypts.
• The degree of atypia related to regenerative
changes decreases in mucosa more distant from
the inflammation.
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